An Introduction to EpiAxis Therapeutics

 

EpiAxis Therapeutics is a leading epigenetic translational drug discovery Company that is focused on the prevention of metastatic disease.  EpiAxis achieves this by targeting the pivotal enzyme system controlling the proliferation of circulating tumor cells (CTC), cancer stem cells (CSC) and, as it has discovered recently, the reinvigoration of immune cells.  This system is the nuclear bound, epigenetic enzyme, lysine-specific demethylase 1 (LSD1).

EpiAxis has a new clinical program based on its family of proprietary, non-catalytic inhibitors, which comprise an optimised family of peptidomimetic inhibitors, with both linear and cyclised variants.  These assets have been developed through the pioneering work of Professor Sudha Rao, a leading epigenetic research scientist.

These first in class inhibitors, were developed following Professor Rao’s discovery of the unique nuclear pocket within the cellular localization sequence of LSD1, which is responsible for its nuclear entry.  The company has since crystallized this novel pocket and has identified lead candidates, which include EPI-112, a highly optimised cyclic peptide version of its highly efficacious EPI-111, a linear peptide with an identical sequence.  This pocket forms an important part of the EPI-110 series’ novel mode of action.

The EpiAxis team is led by Dr Jeremy Chrisp, CEO, and Professor Sudha Rao, CSO. EpiAxis was formed to maximize the commercial value of this proven and pioneering research and to establish partnerships with leading pharmaceutical companies seeking to help develop a novel and effective new class of anti-metastatic cancer drugs. EpiAxis is privately funded at this stage.

 

Professor Sudha Rao